
Biotech Analysts, along with multifocal motor neuropathy (MMN) Expert Dr. Jeffrey Allen, who discusses Dianthus’ (DNTH) and Argenx’s (ARGX) December MMN results on an Analyst/Industry conference call to be held
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| DNTH | Dianthus Therapeutics | 84.25 | 44.14 | 110.03% |
| Name | Price | % Change | |
|---|---|---|---|
| $84.25 | +110.03% |

Biotech Analysts, along with multifocal motor neuropathy (MMN) Expert Dr. Jeffrey Allen, who discusses Dianthus’ (DNTH) and Argenx’s (ARGX) December MMN results on an Analyst/Industry conference call to be held

Reports Q3 revenue $1.21M, consensus $388,660. “The Dianthus (DNTH) team continues to execute on our strategy to build a best-in-disease neuromuscular franchise with claseprubart across gMG, CIDP, and MMN, while

The F/m Emerald Life Sciences Innovation ETF (LFSC) ranks in the 12th percentile of Morningstar’s US Fund Health category, measured against 154 funds over the trailing one-year period as of

Roth Capital initiated coverage of Dianthus (DNTH) with a Buy rating and $113 price target The firm believes claseprubart’s “rapid” clinical activity, infrequent low-volume self-injection, and potential to avoid a

LifeSci Capital analyst Rami Katkhuda maintained a Buy rating on Dianthus Therapeutics today and set a price target of $125.00. Rami Katkhuda has given his Buy rating due to a

16:03 EDT Dianthus (DNTH) files automatic mixed securities shelf Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today’s best-performing stocks on

Biotech Analysts hold a conference call with management on September 18 at 11 am hosted by JPMorgan.Webcast Link Published first on TheFly – the ultimate source for real-time, market-moving breaking

William Blair analyst Myles Minter has reiterated their bullish stance on DNTH stock, giving a Buy rating on September 11. Myles Minter has given his Buy rating due to a

JPMorgan analyst Brian Cheng initiated coverage of Dianthus (DNTH) with an Overweight rating and $135 price target Dianthus is a clinical-stage biotech developing therapeutics for severe autoimmune diseases led by

The most talked about and market moving research calls around Wall Street are now in one place. Here are today’s research calls that investors need to know, as compiled by
| Name | Analyst | Analyst Firm | Rating | Analyst Price Target | Action | Date |
|---|---|---|---|---|---|---|
| buy | Reiterated | Nov 16, 2026 | ||||
| buy | Reiterated | Nov 13, 2026 | ||||
| buy | Reiterated | Nov 6, 2026 | ||||
| buy | Reiterated | Nov 5, 2026 | ||||
| buy | Reiterated | Nov 5, 2026 | ||||
| buy | Reiterated | Nov 5, 2026 | ||||
| buy | Reiterated | Sep 29, 2026 | ||||
| buy | Reiterated | Sep 18, 2026 | ||||
| buy | Initiated | Sep 4, 2026 | ||||
| buy | Reiterated | Aug 10, 2026 |
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Mar 16, 2027TBA | $4.78B | $-0.96 | $448.00K | -0.15 | 2827.67 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.